Beyfortus (RSV)
You will earn 800 points from this product
No Charges till Medical Approval
Beyfortus (nirsevimab) is a long-acting monoclonal antibody that provides passive RSV protection for newborns and infants through their first RSV season with a single intramuscular dose.
- COD Available
- Genuine Quality
Delivery Options
Get delivery at your doorstep
BEYFORTUS (Nirsevimab) - RSV Monoclonal Antibody by Sanofi / AstraZeneca provides passive immunity against Respiratory Syncytial Virus (RSV) - the #1 cause of hospitalisation in infants under 1 year.
- Single IM injection - protection lasts ~5 months (one full RSV season)
- 50mg dose for infants <5kg; 100mg for infants ?5kg
- Not a vaccine - it is a monoclonal antibody (immediate protection, no immune memory required)
- Efficacy: ~70-75% reduction in RSV-related lower respiratory tract illness in trials
- High-risk infants entering second RSV season: 200mg (two 100mg doses)
Review and Ratings
No reviews yet
Be the first to share your experience — it helps other shoppers decide.
You'll be asked to sign in first.